The bill, H.B. No. 3086, amends the Health and Safety Code to enhance reporting requirements for pharmaceutical drug manufacturers regarding prescription drug costs. It mandates that manufacturers submit an annual report by the 15th day of each calendar year, detailing the current wholesale acquisition cost of FDA-approved prescription drugs sold in Texas. Additionally, if a drug experiences a wholesale acquisition cost increase of 40% or more over the past three years, or 15% or more in the previous year, the manufacturer must provide further information, including whether the drug is a brand name or generic, factors contributing to the cost increase, and relevant research and development costs.

The bill also includes provisions for the publication of cost increase information by the department within 60 days of receiving the report and allows the department to assess administrative penalties for violations of the chapter. Notably, it repeals Section 441.0053 and replaces the department's discretion in assessing penalties with a requirement to do so. The changes are set to take effect on September 1, 2025, and the executive commissioner of the Health and Human Services Commission is tasked with adopting necessary rules for implementation.

Statutes affected:
Introduced: Health and Safety Code 441.0051, Health and Safety Code 441.0054, Health and Safety Code 441.0102, Health and Safety Code 441.0053 (Health and Safety Code 441)